MRVI — Maravai Lifesciences Holdings Balance Sheet
0.000.00%
- $930.77m
- $1.20bn
- $259.19m
- 73
- 20
- 37
- 39
Annual balance sheet for Maravai Lifesciences Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 236 | 551 | 632 | 575 | 322 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 51.2 | 118 | 147 | 55.7 | 38.5 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 332 | 740 | 848 | 700 | 429 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 101 | 95.4 | 117 | 223 | 217 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,271 | 1,918 | 2,282 | 1,487 | 1,008 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 131 | 93.8 | 110 | 87.5 | 57 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1,182 | 1,603 | 1,737 | 1,071 | 683 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 88.5 | 315 | 545 | 417 | 325 |
| Total Liabilities & Shareholders' Equity | 1,271 | 1,918 | 2,282 | 1,487 | 1,008 |
| Total Common Shares Outstanding |